Repare Therapeutics announced the receipt of a $40m milestone payment from Roche following the dosing of its first patient in a Phase II clinical trial investigating camonsertib in solid tumours. 

Camonsertibis a precision oncology drug treating cancer by targeting specific genetic alterations in solid tumours. The drug works by inhibiting ataxia telangiectasia and rad3-related protein (ATR), involved in DNA repair and cell cycle regulation. 

Canada-based Repare utilises its SNIPRx platform which screens tumour genes, pinpointing patients who could benefit the most from their therapies, developing precise treatments for specific genetic profiles in tumours. 

Repare received an upfront payment of $125m when the collaboration was announced in July 2022, and is eligible to receive up to $1.2bn on achieving clinical, regulatory and sales milestones. Under the terms of the collaboration, Repare has the option to opt-in for a 50/50 co-development and profit-sharing arrangement in the US market. 

The Phase II TAPISTRY study (NCT04589845) is an open-label, multi-centre trial evaluating the safety and efficacy of camonsertnib in patients with unresectable, locally advanced, or metastatic solid tumours. The eventual 920-patient cohort will receive treatment according to their specific tumour characteristics and genomic alterations. 

Camonsertnib is also being investigated in several other clinical trials. The Phase Ib/II MORPHEUS trial (NCT03337698), evaluating the safety and efficacy of the drug in patients with metastatic non-small cell lung cancer (NSCLC), enrolled the first patient in the camonsertnib-arm in October.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Repare announced data from the Phase I/II TRESR and Ib/II ATTACC trials last year. ATTACC, in collaboration with Roche, is evaluating camonsertib plus two PARPis, niraparib or olaparib, to treat patients with advanced solid tumours, while TRESR is assessing camonsertib in combination with talazoparib poly (ADP-ribose) polymerase inhibitor (PARPi). The overall clinical benefit rate (CBR) for all patients was 48%. 

In the announcement accompanying the milestone, Repare’s CEO Lloyd Segal said: “This milestone is a key achievement for us, demonstrating Roche’s commitment to the global clinical development of camonsertib and highlighting their exploration of development opportunities for camonsertib across multiple tumour types and genetic alterations to maximize patient impact.”